LOGIN
ID
PW
MemberShip
2025-07-10 09:55
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Company
Gastric cancer-targeted therapy 'Vyloy' seeks reimb again
by
Eo, Yun-Ho
Jul 10, 2025 06:10am
Vyloy, a gastric cancer-targeted therapy, is once again vying for inclusion in the National Health Insurance reimbursement list. According to industry sources, Astellas Pharma Korea recently submitted a reimbursement application for Vyloy (zolbetuximab), a targeted treatment for Claudin 18.2-positive gastric cancer. Vyloy did not pass
Opinion
[Reporter¡¯s View] Time to verify K-radiopharmaceuticals
by
Son, Hyung Min
Jul 10, 2025 06:09am
Radiopharmaceuticals are special preparations that combine drugs with radioactive isotopes for diagnostic or therapeutic use. In particular, radioligand therapy (RLT), which delivers radiation directly to tumor cells, is known for its high precision, being referred to as "moving radiation surgery." As beta particle-based radioligand thera
Company
Ono Pharma Korea¡¯s sales double in 4 years with Opdivo
by
Son, Hyung Min
Jul 10, 2025 06:09am
Ono Pharmaceutical Korea continued its sales growth, powered by its immuno-oncology drug Opdivo. The company's sales doubled in 4 years. The company is preparing for the expiration of Opdivo's patent by securing a diverse pipeline of new anticancer drugs, including antibody-drug conjugates (ADCs) and novel immuno-oncology drugs with different me
Policy
Discussion on "Indication-specific drug pricing system"
by
Lee, Tak-Sun
Jul 10, 2025 06:09am
The Health Insurance Review & Assessment Service (HIRA) announced that the issue of 'indication-specific drug pricing system' proposed by the pharmaceutical industry may require further discussion, and the immeditate implementation is difficult. They explained that further discussion is needed, particularly regarding the prevention of co
Policy
Introduction of AI for drug approval and review in Korea
by
Lee, Hye-Kyung
Jul 10, 2025 06:09am
The Ministry of Food and Drug Safety is conducting follow-up research to introduce generative artificial intelligence (AI) to the domestic drug approval and review field starting next year. The Pharmaceutical and Medical Device Research Department of the National Institute of Food and Drug Safety Evaluation is conducting an ISP project to est
Company
Credit ratings for Samsung Biologics¡¤JW Holdings¡è
by
Kim, Jin-Gu
Jul 10, 2025 06:08am
Major pharmaceutical and biotech companies (biopharma companies) are facing varying differing credit ratings and outlooks. While Samsung Biologics and JW Holdings received upward credit ratings, Handok was downgraded. Dong-A ST's credit rating outlook shifted from 'stable' to 'negative'. Credit rating agencies explained that these resul
Company
'Ebglyss' can be prescribed at general hospitals
by
Eo, Yun-Ho
Jul 9, 2025 06:10am
'Ebglyss,' a new drug for the treatment of atopic dermatitis, is now available for prescription at general hospitals. According to industry sources, Lily Korea's interleukin (IL)-13 inhibitor 'Ebglyss (lebrikizumab)' has passed the drug committees (DC) of tertiary general hospitals, including Seoul National University Hospital, Asan Medic
Policy
Daewoong¡¯s generic version of Migbose approved in Korea
by
Lee, Hye-Kyung
Jul 9, 2025 06:09am
Daewoong Pharmaceutical has been approved to sell a generic version of the diabetes treatment Migbose Film-Coated Tablets (miglitol) in Korea. On the 7th, the Ministry of Food and Drug Safety approved Daewoong Pharmaceutical's Daewoong Miglitol Tab. (miglitol). Like the original Migbose, Daewoong Miglitol Tab is a film-coated tablet indica
Company
Adding amiloride effective in resistant hypertension
by
Son, Hyung Min
Jul 9, 2025 06:08am
A new treatment option has been proposed for patients with resistant hypertension that cannot be controlled even with the existing triple combination therapy for hypertension. A regimen combining an olmesartan-based triple combination therapy with the potassium-sparing diuretic ¡®amiloride¡¯ demonstrated similar blood pressure-lowering effec
Opinion
[Reporter's View] The revision of the Commercial Act
by
Kim, Jin-Gu
Jul 9, 2025 06:08am
The bill on revising the Commercial Act has passed the National Assembly. The bill expands the fiduciary duty of directors to include not only the ¡°company¡± but also ¡°shareholders,¡± mandates the introduction of electronic shareholder meetings for listed companies with assets of KRW 2 trillion or more, and changes the title of ¡°outside d
1
2
3
4
5
6
7
8
9
10
>